Stephen Roth, Ph.D., President, Chief Executive Officer

In 1990, while a professor of biology at the University of Pennsylvania, Stephen Roth became the scientific founder of Neose Technologies, Inc. He left Penn to become Neose's chief scientific officer in 1992, and was made chief executive officer and chairman of the board in 1994. He took Neose public in 1996.  In 2002, Dr. Roth brought in a new CEO and remained a director until 2004. Before going to Penn, where Dr. Roth was biology chairman from 1982-1987, he was on the faculty at The Johns Hopkins University from 1970-1980.

Eric Sandquist, Chief Business Officer

Prior to joining Immune Control in June 2007, Mr. Sandquist held a number of senior leadership roles at Merck where he commercialized and launched products in the United States and Europe.  As a vice president at Merck, Mr. Sandquist championed a global strategic initiative to improve product commercialization.  As managing director at Merck, Eric led the Danish subsidiary, competing in nine therapeutic areas, to greater profitability, operational efficiency and market access.  He also led the commercial development and launch of new products within Merck at the global headquarters and subsidiary levels. For example, he was responsible for the global launch of Maxalt® that has yielded $2 billion in cumulative sales.   Mr. Sandquist earned a B.A. in history with honors from the University of Massachusetts, Amherst, and an M.B.A. from Harvard Business School.

David Zopf, M.D., Chief Scientific Officer

David Zopf joined Immune Control in January 2008. His previous experience includes 15 years in various executive roles at Neose Technologies, Inc. where he was most recently executive vice president and chief scientific officer. At Neose he managed discovery and development of new products and technologies and was co-inventor on many patents pertaining to oligosaccharide anti-infectives, and the use of GlycoPEGylationtm technology to develop and manufacture second generation glycoprotein drugs. Dr. Zopf contributed to IND filings that led to five clinical trials, including ongoing trials of long-acting forms of G-CSF and factor VIIa. After receiving his A.B. and M.D. degrees from Washington University, St. Louis, Dr. Zopf pursued an academic career for 17 years at the National Cancer Institute where he served as chief, Section on Biochemical Pathology. During that time he authored more than 70 peer-reviewed publications focused on structure/function relationships of biologically active complex carbohydrates.

Nancy Jean Barnabei, Chief Financial Officer

Prior to joining Immune Control in February 2008, Ms. Barnabei provided financial and strategic advisory services to biotechnology companies. From 2000-2004, she was vice president of finance, treasurer and chief financial officer at Locus Pharmaceuticals where she raised $94 million in venture and debt financing, and directed the company’s growth from 5 to 75 employees, strategic planning, investor relations, and human resources. Her previous experience includes eight years at Cephalon, most recently as corporate controller. As corporate controller, Ms. Barnabei was responsible for developing and managing accounting and financial reporting systems, annual budget processes, long-range planning, contract management, SEC reporting, worldwide tax strategy and treasury. Ms. Barnabei earned a B.S. in Business Administration from Northeastern University and is a certified public accountant.

Elliot Morales, Jr., Vice President, Operations

Elliot Morales, Jr. joined Immune Control in September 2008. His previous experience includes 11 years in various leadership roles at Neose Technologies, most recently as vice president, project management and analytical operations. In this role Mr. Morales directed the project and program management function for internal and external collaborations and managed numerous preclinical development studies. Prior to joining Neose, he held product development and quality control positions at Direct Access Diagnostics and Ortho Diagnostic Systems, both Johnson & Johnson companies. Mr. Morales received his B.A. in biochemistry from Rutgers College, and his M.B.A. from Rutgers, Graduate School of Management.

Clayton A. Buck, Ph.D., Director of RD

Dr. Buck served as The Wistar Institute's acting director and CEO from September 2000 to June 2002. He became vice president for academic affairs from 2002 until his retirement in December 2004. Dr. Buck holds a B.S. in biology from Kansas State University and a Ph.D. in microbiology from Montana State University. After completing a postdoctoral fellowship at the University of California, Irvine, he joined the University of Pennsylvania as assistant professor of therapeutic research. In 1975, he joined The Wistar Institute as professor and became a member of The Wistar Institute Cancer Center. At Wistar, Clayton was director of scientific development between 1990 and 1992. From 1992 to 1999, he was deputy director of the institute. While at the Wistar Institute, he co-discovered the class of proteins now known as the integrins, and has made other major contributions to the field of cell-cell and cell-matrix adhesion and the roles of specific adhesion receptors in cancer and cardiovascular development. Dr. Buck was editor-in-chief of the journal Cell Adhesion and Communication from 1992 to 1999, and has served as a referee for many leading journals, including Science, Nature, Cell, Journal of Cell Biology, Journal of Clinical Investigation, Journal of Cell Science, and Development Biology. Dr. Buck is co-author of more than 115 publications including scientific papers, reviews, conference presentations, and book chapters.